Wei Zhu1, Peter F Doubleday2, Daniel S Catlin3, Pathum M Weerawarna1, Arseniy Butrin3, Sida Shen1, Zdzislaw Wawrzak4, Neil L Kelleher1,2, Dali Liu3, Richard B Silverman1,2,5. 1. Department of Chemistry, Chemistry of Life Processes Institute, Center for Molecular Innovation and Drug Discovery, and Center for Developmental Therapeutics, Northwestern University, Evanston, Illinois 60208, United States. 2. Department of Molecular Biosciences, Northwestern University, Evanston, Illinois 60208, United States. 3. Department of Chemistry and Biochemistry, Loyola University Chicago, Chicago, Illinois 60660, United States. 4. Synchrotron Research Center, LS-CAT, Sector 21, Northwestern University, Lemont, Illinois 60439, United States. 5. Department of Pharmacology, Northwestern University, Chicago, Illinois 60611, United States.
Abstract
Human ornithine aminotransferase (hOAT), a pyridoxal 5'-phosphate-dependent enzyme, plays a critical role in the progression of hepatocellular carcinoma (HCC). Pharmacological selective inhibition of hOAT has been shown to be a potential therapeutic approach for HCC. Inspired by the discovery of the nonselective aminotransferase inactivator (1R,3S,4S)-3-amino-4-fluoro cyclopentane-1-carboxylic acid (1), in this work, we rationally designed, synthesized, and evaluated a novel series of fluorine-substituted cyclohexene analogues, thereby identifying 8 and 9 as novel selective hOAT time-dependent inhibitors. Intact protein mass spectrometry and protein crystallography demonstrated 8 and 9 as covalent inhibitors of hOAT, which exhibit two distinct inactivation mechanisms resulting from the difference of a single fluorine atom. Interestingly, they share a similar turnover mechanism, according to the mass spectrometry-based analysis of metabolites and fluoride ion release experiments. Molecular dynamics (MD) simulations and electrostatic potential (ESP) charge calculations were conducted, which elucidated the significant influence of the one-fluorine difference on the corresponding intermediates, leading to two totally different inactivation pathways. The novel addition-aromatization inactivation mechanism for 9 contributes to its significantly enhanced potency, along with excellent selectivity over other aminotransferases.
Humann class="Gene">ornithine aminotransferase (hOAT), a pyridoxal 5'-phosphate-dependent enzyme, plays a critical role in the progression of hepatocellular carcinoma (HCC). Pharmacological selective inhibition of hOAT has been shown to be a potential therapeutic approach for HCC. Inspired by the discovery of the nonselective aminotransferase inactivator (1R,3S,4S)-3-amino-4-fluoro cyclopentane-1-carboxylic acid (1), in this work, we rationally designed, synthesized, and evaluated a novel series of fluorine-substituted cyclohexene analogues, thereby identifying 8 and 9 as novel selective hOAT time-dependent inhibitors. Intact protein mass spectrometry and protein crystallography demonstrated 8 and 9 as covalent inhibitors of hOAT, which exhibit two distinct inactivation mechanisms resulting from the difference of a single fluorine atom. Interestingly, they share a similar turnover mechanism, according to the mass spectrometry-based analysis of metabolites and fluoride ion release experiments. Molecular dynamics (MD) simulations and electrostatic potential (ESP) charge calculations were conducted, which elucidated the significant influence of the one-fluorine difference on the corresponding intermediates, leading to two totally different inactivation pathways. The novel addition-aromatization inactivation mechanism for 9 contributes to its significantly enhanced potency, along with excellent selectivity over other aminotransferases.
Authors: Yue Pan; Madina R Gerasimov; Trine Kvist; Petrine Wellendorph; Karsten K Madsen; Elena Pera; Hyunbeom Lee; Arne Schousboe; Mary Chebib; Hans Bräuner-Osborne; Cheryl M Craft; Jonathan D Brodie; Wynne K Schiffer; Stephen L Dewey; Steven R Miller; Richard B Silverman Journal: J Med Chem Date: 2011-12-30 Impact factor: 7.446
Authors: Jessica De Ingeniis; Boris Ratnikov; Adam D Richardson; David A Scott; Pedro Aza-Blanc; Surya K De; Marat Kazanov; Maurizio Pellecchia; Ze'ev Ronai; Andrei L Osterman; Jeffrey W Smith Journal: PLoS One Date: 2012-09-14 Impact factor: 3.240
Authors: Hyunbeom Lee; Emma H Doud; Rui Wu; Ruslan Sanishvili; Jose I Juncosa; Dali Liu; Neil L Kelleher; Richard B Silverman Journal: J Am Chem Soc Date: 2015-02-10 Impact factor: 15.419
Authors: Dorothee Liebschner; Pavel V Afonine; Nigel W Moriarty; Billy K Poon; Oleg V Sobolev; Thomas C Terwilliger; Paul D Adams Journal: Acta Crystallogr D Struct Biol Date: 2017-02-01 Impact factor: 7.652
Authors: Wei Zhu; Arseniy Butrin; Rafael D Melani; Peter F Doubleday; Glaucio Monteiro Ferreira; Mauricio T Tavares; Thahani S Habeeb Mohammad; Brett A Beaupre; Neil L Kelleher; Graham R Moran; Dali Liu; Richard B Silverman Journal: J Am Chem Soc Date: 2022-03-16 Impact factor: 16.383
Authors: Arseniy Butrin; Brett A Beaupre; Noel Kadamandla; Peidong Zhao; Sida Shen; Richard B Silverman; Graham R Moran; Dali Liu Journal: ACS Chem Biol Date: 2020-12-14 Impact factor: 5.100
Authors: Wei Zhu; Peter F Doubleday; Arseniy Butrin; Pathum M Weerawarna; Rafael D Melani; Daniel S Catlin; Timothy A Dwight; Dali Liu; Neil L Kelleher; Richard B Silverman Journal: J Am Chem Soc Date: 2021-05-20 Impact factor: 16.383
Authors: Sida Shen; Arseniy Butrin; Peter F Doubleday; Rafael D Melani; Brett A Beaupre; Mauricio T Tavares; Glaucio M Ferreira; Neil L Kelleher; Graham R Moran; Dali Liu; Richard B Silverman Journal: J Am Chem Soc Date: 2021-06-07 Impact factor: 16.383